Information Update - Update: Pfizer recalls Accupril blood pressure tablets due to a nitrosamine impurity

OTTAWA, ON, April 21, 2022 /CNW/ - Pfizer Canada ULC is recalling all lots of the prescription drug Accupril (quinapril hydrochloride) in 10 mg, 20 mg and 40 mg strengths due to the presence of a nitrosamine impurity (N-nitroso-quinapril) above the acceptable level.

Long-term exposure to N-nitroso-quinapril at a level above what is considered acceptable may increase the risk of cancer. This impurity is not expected to cause harm when ingested at or below the acceptable level. A person taking a drug that contains this impurity at or below the acceptable level every day for 70 years is not expected to have an increased risk of cancer.

Health Canada maintains a list of recalled quinapril drugs affected by this issue. Please see the full advisory for more information, including more on the risk and what patients should do.

Affected Products

Product	DIN	Lot	Expiry
Accupril 10mg	01947672	DY3042	2023-03-31
Accupril 10mg	01947672	CK5285	2022-05-31
Accupril 20mg	01947680	DT9592	2023-03-31
Accupril 20mg	01947680	CK6258	2022-05-31
Accupril 20mg	01947680	CK6259	2022-05-31
Accupril 40mg	01947699	DT9591	2023-03-31
Accupril 40mg	01947699	CM2828	2022-05-31
Accupril 40mg	01947699	CM2829	2022-05-31

Également disponible en français

SOURCE Health Canada

Media Inquiries: Health Canada, [phone], [email protected]; Public Inquiries:[phone], 1-866 225-0709, [email protected]